Doximity, Inc. (NASDAQ:DOCS) Director Kira Scherer Wampler Sells 2,500 Shares

Doximity, Inc. (NASDAQ:DOCS) Director Kira Scherer Wampler sold 2,500 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $28.00, for a total transaction of $70,000.00. Following the completion of the sale, the director now owns 10,258 shares in the company, valued at $287,224. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kira Scherer Wampler also recently made the following trade(s):

• On Friday, May 17th, Kira Scherer Wampler sold 2,500 shares of Doximity stock. The stock was sold at an average price of $27.22, for a total transaction of $68,050.00.

Doximity Stock Performance

Doximity stock traded down $0.51 during mid-day trading on Tuesday, reaching $26.96. The company’s stock had a trading volume of 2,791,771 shares, compared to its average volume of 1,718,913. The company has a market capitalization of $5.00 billion, a price-to-earnings ratio of 38.17, a price-to-earnings-growth ratio of 5.23 and a beta of 1.22. Doximity, Inc. has a 12 month low of $19.71 and a 12 month high of $36.29. The business’s 50 day simple moving average is $26.70 and its 200 day simple moving average is $27.49.

Doximity (NASDAQ:DOCS) last released its earnings results on Thursday, May 16th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.04. The business had revenue of $118.06 million during the quarter, compared to the consensus estimate of $116.46 million. Doximity had a net margin of 31.04% and a return on equity of 17.44%. As a group, sell-side analysts expect that Doximity, Inc. will post 0.74 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. William Blair reiterated an “outperform” rating on shares of Doximity in a report on Friday, May 17th. JPMorgan Chase & Co. upgraded shares of Doximity from an “underweight” rating to a “neutral” rating and set a $25.00 price objective on the stock in a report on Thursday, April 25th. Morgan Stanley restated an “underweight” rating and set a $25.00 price objective on shares of Doximity in a report on Tuesday, April 23rd. Evercore ISI raised their price objective on shares of Doximity from $28.00 to $29.00 and gave the stock an “in-line” rating in a report on Friday, May 17th. Finally, Needham & Company LLC restated a “hold” rating on shares of Doximity in a report on Friday, May 17th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Doximity has an average rating of “Hold” and a consensus target price of $28.73.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. First Horizon Advisors Inc. grew its position in shares of Doximity by 111.3% in the 4th quarter. First Horizon Advisors Inc. now owns 995 shares of the company’s stock valued at $28,000 after acquiring an additional 524 shares during the period. LRI Investments LLC acquired a new stake in shares of Doximity during the 1st quarter worth about $27,000. GAMMA Investing LLC acquired a new stake in shares of Doximity during the 4th quarter worth about $40,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Doximity during the 1st quarter worth about $46,000. Finally, Essex Investment Management Co. LLC acquired a new stake in shares of Doximity during the 1st quarter worth about $73,000. Institutional investors own 87.19% of the company’s stock.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.